当前位置: 首页 >> 检索结果
5041. Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics.
作者: Huamei He.;Tomas Baka.;James Balschi.;Alykhan S Motani.;Kathy K Nguyen.;Qingxiang Liu.;Rebecca Slater.;Brooke Rock.;Chen Wang.;Christopher Hale.;Georgios Karamanlidis.;James J Hartman.;Fady I Malik.;Jeff D Reagan.;Ivan Luptak.
来源: Circ Heart Fail. 2022年15卷3期e009195页
Current heart failure therapies unload the failing heart without targeting the underlying problem of reduced cardiac contractility. Traditional inotropes (ie, calcitropes) stimulate contractility via energetically costly augmentation of calcium cycling and worsen patient survival. A new class of agents-myotropes-activates the sarcomere directly, independent of calcium. We hypothesize that a novel myotrope TA1 increases contractility without the deleterious myocardial energetic impact of a calcitrope dobutamine.
5042. Comparison of a Pure Plug-Based Versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial.
作者: Mohamed Abdel-Wahab.;Philipp Hartung.;Oliver Dumpies.;Danilo Obradovic.;Johannes Wilde.;Nicolas Majunke.;Peter Boekstegers.;Ralf Müller.;Melchior Seyfarth.;Marc Vorpahl.;Philipp Kiefer.;Thilo Noack.;Sergey Leontyev.;Marcus Sandri.;Johannes Rotta Detto Loria.;Mitsunobu Kitamura.;Michael Andrew Borger.;Anne-Kathrin Funkat.;Sven Hohenstein.;Steffen Desch.;David Holzhey.;Holger Thiele.; .
来源: Circulation. 2022年145卷3期170-183页
Transcatheter aortic valve replacement is an established treatment option for patients with severe symptomatic aortic stenosis and is most commonly performed through the transfemoral access route. Percutaneous access site closure can be achieved using dedicated plug-based or suture-based vascular closure device (VCD) strategies, but randomized comparative studies are scarce.
5043. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
作者: Kai-Ni Shen.;Wei-Jun Fu.;Yu Wu.;Yu-Jun Dong.;Zhong-Xia Huang.;Yong-Qiang Wei.;Chun-Rui Li.;Chun-Yan Sun.;Ye Chen.;Hui-Lei Miao.;Yue-Lun Zhang.;Xin-Xin Cao.;Dao-Bin Zhou.;Jian Li.
来源: Circulation. 2022年145卷1期8-17页
Doxycycline was demonstrated in a retrospective study to be associated with greater survival in patients with light chain amyloidosis. Therefore, we prospectively compared the efficacy of bortezomib-cyclophosphamide-dexamethasone (CyBorD) and CyBorD combined with doxycycline for cardiac light chain amyloidosis.
|